Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  HIV Infection

  Free Subscription


23.05.2022

1 AIDS
6 AIDS Res Hum Retroviruses
2 Antimicrob Agents Chemother
1 Antivir Ther
1 BMC Immunol
3 Clin Infect Dis
2 HIV Med
4 J Acquir Immune Defic Syndr
1 J Clin Invest
1 J Immunol
3 J Med Virol
1 J Virol
1 Lancet
3 Lancet Infect Dis
1 MMWR Morb Mortal Wkly Rep
1 Nat Med
3 Nature
17 PLoS One
1 PLoS Pathog
3 Proc Natl Acad Sci U S A
3 Vaccine


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AIDS

  1. GIOVENCO D, Pettifor A, Powers KA, Hightow-Weidman L, et al
    Intimate partner violence and oral HIV pre-exposure prophylaxis adherence among young African women.
    AIDS. 2022 May 17. pii: 00002030-990000000-00015.
    PubMed         Abstract available


    AIDS Res Hum Retroviruses

  2. FULLER D, O'Connor MA
    Letter to the Editor on Guerriero et al.: Prior infection with coccidioidomycosis in nonhuman primates and impact on SIV disease and vaccine immunogenicity.
    AIDS Res Hum Retroviruses. 2022 Feb 16. doi: 10.1089/AID.2021.0236.
    PubMed         Abstract available

  3. TASHIRO Y, Matsuura E, Sagara Y, Nozuma S, et al
    High Prevalence of HTLV-1 Carriers Among the Elderly Population in Kagoshima, a Highly Endemic Area in Japan.
    AIDS Res Hum Retroviruses. 2022;38:363-369.
    PubMed         Abstract available

  4. SABERI P, Campbell C, Sauceda JA, Ndukwe SO, et al
    Perceptions of risks and benefits of participating in HIV cure-related research among diverse young adults living with HIV in the United States: qualitative research findings.
    AIDS Res Hum Retroviruses. 2022 May 17. doi: 10.1089/AID.2021.0192.
    PubMed         Abstract available

  5. MALAMA K, Logie CH, Narasimhan M, Ouedraogo L, et al
    Short Communication vertical line Awareness of HIV self-care interventions across global regions: results from a values and preferences survey.
    AIDS Res Hum Retroviruses. 2022 May 17. doi: 10.1089/AID.2021.0200.
    PubMed         Abstract available

  6. DE SCHACHT C, Lucas C, Paulo P, Van Rompaey S, et al
    Reaching males and young adults in a pharmacy-based HIV self-testing strategy: Results from an acceptability study in Mozambique.
    AIDS Res Hum Retroviruses. 2022 May 17. doi: 10.1089/AID.2021.0116.
    PubMed         Abstract available

  7. SHRESTHA I, Ming K, Jimenez V, Wendelborn J, et al
    Lessons learned from an HIV pre-exposure prophylaxis coordination program in San Francisco primary care clinics.
    AIDS Res Hum Retroviruses. 2022 May 20. doi: 10.1089/AID.2022.0013.
    PubMed         Abstract available


    Antimicrob Agents Chemother

  8. DE NICOLO A, Calcagno A, Motta I, De Vivo E, et al
    The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study.
    Antimicrob Agents Chemother. 2022 May 18:e0013622. doi: 10.1128/aac.00136.
    PubMed         Abstract available

  9. DIAMOND TL, Ngo W, Xu M, Goh SL, et al
    Islatravir Has a High Barrier to Resistance and Exhibits a Differentiated Resistance Profile from Approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs).
    Antimicrob Agents Chemother. 2022 May 12:e0013322. doi: 10.1128/aac.00133.
    PubMed         Abstract available


    Antivir Ther

  10. MUSENGIMANA G, Tuyishime E, Kiromera A, Malamba SS, et al
    Acquired HIV drug resistance among adults living with HIV receiving first-line antiretroviral therapy in Rwanda: A cross-sectional nationally representative survey.
    Antivir Ther. 2022;27:13596535221102690.
    PubMed         Abstract available


    BMC Immunol

  11. KAUSALYA B, Saravanan S, Pallikkuth S, Pahwa R, et al
    Immune correlates of cardiovascular co-morbidity in HIV infected participants from South India.
    BMC Immunol. 2022;23:24.
    PubMed         Abstract available


    Clin Infect Dis

  12. COX H, Workman L, Bateman L, Franckling-Smith Z, et al
    Oral swabs tested with Xpert MTB/RIF Ultra for diagnosis of pulmonary tuberculosis in children: a diagnostic accuracy study.
    Clin Infect Dis. 2022 May 17. pii: 6586837. doi: 10.1093.
    PubMed         Abstract available

  13. KAMAU E, Chaudhury S, Bolton JS, Slike BM, et al
    Susceptibility to HIV-1 Acquisition linked to Malaria Exposure: A Case-control Study.
    Clin Infect Dis. 2022 May 20. pii: 6589785. doi: 10.1093.
    PubMed         Abstract available

  14. TORDOFF DM, Dombrowski JC, Ramchandani MS, Barbee LA, et al
    Trans-inclusive Sexual Health Questionnaire to Improve HIV/STI Care for Transgender Patients: Anatomic-site Specific STI Prevalence & Screening Rates.
    Clin Infect Dis. 2022 May 20. pii: 6589775. doi: 10.1093.
    PubMed         Abstract available


    HIV Med

  15. GIZAW A, King WC, Hinerman AS, Chung RT, et al
    A prospective cohort study of renal function and bone turnover in adults with hepatitis B virus (HBV)-HIV co-infection with high prevalence of tenofovir-based antiretroviral therapy use.
    HIV Med. 2022 May 16. doi: 10.1111/hiv.13322.
    PubMed         Abstract available

  16. YU H, Yang Y, Cao D, Zhao Y, et al
    Association of low-level viremia with mortality among people living with HIV on antiretroviral therapy in Dehong, Southwest China: A retrospective cohort study.
    HIV Med. 2022 May 16. doi: 10.1111/hiv.13320.
    PubMed         Abstract available


    J Acquir Immune Defic Syndr

  17. JONES DL, Zhang Y, Rodriguez VJ, Haberlen S, et al
    Association of PTSD with Longitudinal COVID-19 Burden in a Mixed-Serostatus Cohort of Men and Women: Weathering the Storm.
    J Acquir Immune Defic Syndr. 2022 May 19. pii: 00126334-990000000-00048.
    PubMed         Abstract available

  18. GARNER BR, Burrus O, Ortiz A, Tueller SJ, et al
    A longitudinal mixed-methods examination of Positive Health Check: Implementation results from a type 1 effectiveness-implementation hybrid trial.
    J Acquir Immune Defic Syndr. 2022 May 18. pii: 00126334-990000000-00044.
    PubMed         Abstract available

  19. HILL BJ, Motley DN, Rosentel K, VandeVusse A, et al
    Employment as HIV prevention: An employment support intervention for adolescent men who have sex with men and adolescent transgender women of color.
    J Acquir Immune Defic Syndr. 2022 May 12. pii: 00126334-990000000-00045.
    PubMed         Abstract available

  20. JAWA R, Walley AY, Wilson DJ, Green TC, et al
    Prescribe to Save Lives: Improving buprenorphine prescribing among HIV clinicians.
    J Acquir Immune Defic Syndr. 2022 May 18. pii: 00126334-990000000-00047.
    PubMed         Abstract available


    J Clin Invest

  21. BALLE C, Armistead B, Kiravu A, Song X, et al
    Factors influencing maternal microchimerism throughout infancy and its impact on infant T cell immunity.
    J Clin Invest. 2022 May 12. pii: 148826. doi: 10.1172/JCI148826.
    PubMed         Abstract available


    J Immunol

  22. UNUTMAZ D
    CCR5: The Receptor That Unlocks the Door for HIV Entry into Cells.
    J Immunol. 2022;208:2459-2460.
    PubMed        


    J Med Virol

  23. MALONGA GA, Dienta S, Traore FT, Maiga Z, et al
    Human Herpesvirus 8 seroprevalence among blood donors in Mali.
    J Med Virol. 2022 May 11. doi: 10.1002/jmv.27850.
    PubMed         Abstract available

  24. CHU FL, Li C, Chen L, Dong B, et al
    Respiratory viruses among pediatric inpatients with acute lower respiratory tract infections in Jinan, China, 2016-2019.
    J Med Virol. 2022 May 20. doi: 10.1002/jmv.27875.
    PubMed         Abstract available

  25. CAI S, Liao G, Yu T, Gao Q, et al
    Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in people living with HIV: A cross-sectional study.
    J Med Virol. 2022 May 18. doi: 10.1002/jmv.27872.
    PubMed         Abstract available


    J Virol

  26. PEI Z, Wang H, Zhao Z, Chen X, et al
    Chemokine PF4 Inhibits EV71 and CA16 Infections at the Entry Stage.
    J Virol. 2022 May 17:e0043522. doi: 10.1128/jvi.00435.
    PubMed         Abstract available


    Lancet

  27. WATTS G
    Luc Antoine Montagnier.
    Lancet. 2022;399:1862.
    PubMed        


    Lancet Infect Dis

  28. KELLY JD, Van Ryn C, Badio M, Fayiah T, et al
    Clinical sequelae among individuals with pauci-symptomatic or asymptomatic Ebola virus infection and unrecognised Ebola virus disease in Liberia: a longitudinal cohort study.
    Lancet Infect Dis. 2022 May 16. pii: S1473-3099(22)00127.
    PubMed         Abstract available

  29. MOYO S, Ismail F, Van der Walt M, Ismail N, et al
    Prevalence of bacteriologically confirmed pulmonary tuberculosis in South Africa, 2017-19: a multistage, cluster-based, cross-sectional survey.
    Lancet Infect Dis. 2022 May 17. pii: S1473-3099(22)00149.
    PubMed         Abstract available

  30. LO NC, Bezerra FSM, Colley DG, Fleming FM, et al
    Review of 2022 WHO guidelines on the control and elimination of schistosomiasis.
    Lancet Infect Dis. 2022 May 17. pii: S1473-3099(22)00221.
    PubMed         Abstract available


    MMWR Morb Mortal Wkly Rep

  31. LEE K, Trujillo L, Olansky E, Robbins T, et al
    Factors Associated with Use of HIV Prevention and Health Care Among Transgender Women - Seven Urban Areas, 2019-2020.
    MMWR Morb Mortal Wkly Rep. 2022;71:673-679.
    PubMed         Abstract available


    Nat Med

  32. JULG B, Stephenson KE, Wagh K, Tan SC, et al
    Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial.
    Nat Med. 2022 May 12. pii: 10.1038/s41591-022-01815.
    PubMed         Abstract available


    Nature

  33. SURYAWANSHI RK, Chen IP, Ma T, Syed AM, et al
    Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination.
    Nature. 2022 May 18. pii: 10.1038/s41586-022-04865.
    PubMed         Abstract available

  34. MALEBRANCHE D
    HIV Care Has Improved Dramatically-But Not for Everyone.
    Nature. 2022;605:S24-S25.
    PubMed        

  35. URAKI R, Kiso M, Iida S, Imai M, et al
    Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2.
    Nature. 2022 May 16. pii: 10.1038/s41586-022-04856.
    PubMed         Abstract available


    PLoS One

  36. FACENTE SN, Grinstein R, Bruhn R, Kaidarova Z, et al
    Hepatitis C prevalence and key population size estimate updates in San Francisco: 2015 to 2019.
    PLoS One. 2022;17:e0267902.
    PubMed         Abstract available

  37. KAZIBWE A, Oryokot B, Mugenyi L, Kagimu D, et al
    Incidence of tuberculosis among PLHIV on antiretroviral therapy who initiated isoniazid preventive therapy: A multi-center retrospective cohort study.
    PLoS One. 2022;17:e0266285.
    PubMed         Abstract available

  38. GALVAN FH, Liu H, Brooks RA, Chen YT, et al
    Using social and sexual networking mobile applications to promote HIV testing, medical care and prevention services among Latino men who have sex with men in Los Angeles County, California, USA.
    PLoS One. 2022;17:e0268406.
    PubMed         Abstract available

  39. SALOMON A, Law S, Johnson C, Baddeley A, et al
    Interventions to improve linkage along the HIV-tuberculosis care cascades in low- and middle-income countries: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0267511.
    PubMed         Abstract available

  40. HAMILTON FW, Somers J, Mitchell RE, Ghazal P, et al
    HMOX1 genetic polymorphisms and outcomes in infectious disease: A systematic review.
    PLoS One. 2022;17:e0267399.
    PubMed         Abstract available

  41. MARQUEZ LK, Ingiliz P, Boesecke C, Krznaric I, et al
    Establishing a framework towards monitoring HCV microelimination among men who have sex with men living with HIV in Germany: A modeling analysis.
    PLoS One. 2022;17:e0267853.
    PubMed         Abstract available

  42. MILLER L, Prieto Merino D, Baisley K, Hayes R, et al
    Hidden heterogeneity: Uncovering patterns of adherence in microbicide trials for HIV prevention.
    PLoS One. 2022;17:e0267011.
    PubMed         Abstract available

  43. BROWN DA, O'Brien KK, Harding R, Sedgwick PM, et al
    Prevalence, severity, and risk factors of disability among adults living with HIV accessing routine outpatient HIV care in London, United Kingdom (UK): A cross-sectional self-report study.
    PLoS One. 2022;17:e0267271.
    PubMed         Abstract available

  44. RAYANAKORN A, Chautrakarn S, Intawong K, Chariyalertsak C, et al
    A comparison of attitudes and knowledge of pre-exposure prophylaxis (PrEP) between hospital and Key Population Led Health Service providers: Lessons for Thailand's Universal Health Coverage implementation.
    PLoS One. 2022;17:e0268407.
    PubMed         Abstract available

  45. WAGNER LD, Minnis AM, Shea J, Agot K, et al
    Female and male partner perspectives on placebo Multipurpose Prevention Technologies (MPTs) used by women in the TRIO study in South Africa and Kenya.
    PLoS One. 2022;17:e0265303.
    PubMed         Abstract available

  46. MUGENYI L, Nanfuka M, Byawaka J, Agaba C, et al
    Effect of universal test and treat on retention and mortality among people living with HIV-infection in Uganda: An interrupted time series analysis.
    PLoS One. 2022;17:e0268226.
    PubMed         Abstract available

  47. BRATTGARD H, Bjorkman P, Nowak P, Treutiger CJ, et al
    Factors associated with low-level viraemia in people with HIV starting antiretroviral therapy: A Swedish observational study.
    PLoS One. 2022;17:e0268540.
    PubMed         Abstract available

  48. ESEMU LF, Awanakam H, Nanfa D, Besong M, et al
    Expression profiles of miR3181 and miR199a in plasma and placenta of virally suppressed HIV-1 infected Cameroonian pregnant women at delivery.
    PLoS One. 2022;17:e0268820.
    PubMed         Abstract available

  49. BIVE BZ, Sacheli R, Situakibanza Nani-Tuma H, Kabututu Zakayi P, et al
    Clinical epidemiology and high genetic diversity amongst Cryptococcus spp. isolates infecting people living with HIV in Kinshasa, Democratic Republic of Congo.
    PLoS One. 2022;17:e0267842.
    PubMed         Abstract available

  50. KAUFMAN E, Williamson T, Mayrand MH, Burchell AN, et al
    Identifying risk factors for prevalent anal human papillomavirus type 16 infection in women living with HIV.
    PLoS One. 2022;17:e0268521.
    PubMed         Abstract available

  51. LEMMET T, Cotte L, Allavena C, Huleux T, et al
    High syphilis prevalence and incidence in people living with HIV and Preexposure Prophylaxis users: A retrospective review in the French Dat'AIDS cohort.
    PLoS One. 2022;17:e0268670.
    PubMed         Abstract available

  52. RICH C, Mavhu W, France NF, Munatsi V, et al
    Exploring the beliefs, experiences and impacts of HIV-related self-stigma amongst adolescents and young adults living with HIV in Harare, Zimbabwe: A qualitative study.
    PLoS One. 2022;17:e0268498.
    PubMed         Abstract available


    PLoS Pathog

  53. SCHAPIRO HM, Khasnis MD, Ahn K, Karagiaridi A, et al
    Regulation of epitope exposure in the gp41 membrane-proximal external region through interactions at the apex of HIV-1 Env.
    PLoS Pathog. 2022;18:e1010531.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  54. HORVATH S, Lu AT, Haghani A, Zoller JA, et al
    DNA methylation clocks for dogs and humans.
    Proc Natl Acad Sci U S A. 2022;119:e2120887119.
    PubMed         Abstract available

  55. MANRY J, Bastard P, Gervais A, Le Voyer T, et al
    The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.
    Proc Natl Acad Sci U S A. 2022;119:e2200413119.
    PubMed         Abstract available

  56. TAURA M, Frank JA, Takahashi T, Kong Y, et al
    APOBEC3A regulates transcription from interferon-stimulated response elements.
    Proc Natl Acad Sci U S A. 2022;119:e2011665119.
    PubMed         Abstract available


    Vaccine

  57. CHAMBERS C, Deeks SL, Sutradhar R, Cox J, et al
    Increases in human papillomavirus vaccine coverage over 12 months among a community-recruited cohort of gay, bisexual, and other men who have sex with men in Canada.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00590.
    PubMed         Abstract available

  58. CUMMINS NW, Badley AD
    Could proteasome inhibition improve therapeutic vaccine response in HIV?
    Vaccine. 2022 May 12. pii: S0264-410X(22)00578.
    PubMed        

  59. NAULT L, Marchitto L, Goyette G, Tremblay-Sher D, et al
    Covid-19 vaccine immunogenicity in people living with HIV-1.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00543.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO HIV Infection is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: